Tables
1.1.1Private OOP spending is the largest source of funding for health among LICs and LMICS
1.1.2Share of government expenditure for health, education, military and debt interest payments, 2019
2.2.1Value-based formulary tiers, incremental cost–effectiveness ratio thresholds and co-payment levels
2.2.2Current 69 priority health problems in the AUGE benefits package
2.3.1Evidence on demand- and supply-side disinvesting interventions
2.3.2Surgical procedures under the remit of phase one of the NHS England EBI programme
2.5.1Higher-income countries tend to favour a mix of public, non-profit and for-profit provision of LTC
2.5.2Overview of the use of means-testing in public support for LTC
3.1.1The impact of different primary care payment models on health care system objectives
3.3.2Countries in the EU by highest/lowest prevalence of informal payments, 2021
3.3.3Countries in Asia by highest/lowest prevalence of informal payments, 2020
3.5.1Payment methods to support coordinated and integrated care
3.6.1Risk adjusters used in needs-based formulae for allocating pooled funds, 2018
3.6.2Types of payment for nursing/care homes used in different countries
3.8.1International guiding instruments to frame public health threats and events and establish preparedness capacities
3.9.1A selection of push and pull mechanisms available or proposed for incentivizing antibiotic R&D
3.10.1Neglected diseases affect more than 1 billion people globally
3.10.2Advantages and disadvantages of incentive mechanisms for innovation and access to innovation
3.10.3PDPs have increased overall investment in R&D and innovation for neglected diseases
3.10.5Fiscal incentives’ effectiveness in stimulating neglected disease research is unclear
3.10.6PRVs’ impact on R&D is unclear because of a lack of data
Open access